The first ever at-home rapid STD test on the market.
The Opportunity
According to the CDC, in 2022, more than 2.5 million cases of syphilis, gonorrhea, and chlamydia were reported in the US. However, the rates of STD testing have not kept up with the growing number of STD cases.
Most common bacterial STDs are easily treatable with prescription antibiotics. But when left untreated, there are serious long-term health risks, including infertility and Pelvic Inflammatory Disease (PID).
Treatment is complicated by the fact that people with common STDs like chlamydia and gonorrhea could be asymptomatic for months, unknowingly spreading the infection to their sexual partners. For example, 50% of men & 70% of women infected with Chlamydia don’t show symptoms upon infection (NHS).
The Solution
Regular STD testing. It sounds simple, but when doctor’s appointments with probing questions or “at-home” tests with messy mail-in samples stand in the way of results, few people willingly subject themselves to this important care.
When our client approached us with a first-of-its-kind rapid STD test that could truly be taken and interpreted at home, we immediately saw the potential to improve access to STD care.
Go-To-Market Strategy
Developed and implemented a roadmap for a full go-to-market strategy, including e-commerce launch, paid and organic media efforts, and supply chain optimization.
Ecommerce website
Built a fully integrated web customer order experience that enabled both test purchase and telehealth consultation with licensed doctors. Our data engineers developed tracking that ensured customers could move seamlessly from Know checkout to doctor check-ins with our telehealth partner.
“We built Know for easy access to high quality clinical care to keep you safe and informed about your sexual health. Know gives you peace of mind and access to the right treatment and compassionate doctor consultations.”
Dr Jonah Mink, MD
Brand Colors
